Skip to main content

Table 1 Characteristics of eligible trials in the meta-analysis

From: Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis

Trial Year Median age(LD) Median age(D) Tumor type Total Number of patients LD D   Control arm drug Dose of anthracyclines Liposomal anthracyclines
Gill et al. [22] 1996 37 37 AIDS-KS 232 116 111 Doxorubicin L dauno-40 mg/m2
Doxo-10 mg/m2
Lipo- Dauno
Northfelt et al. [23] 1998 36 38 AIDS-KS 258 133 125 Doxorubicin PLD-20 mg/m2
D-20 mg/m2
PLD
Judson et al. [24] 2000 52 52 Metastatic soft tissue sarcoma 94 50 44 Doxorubicin PLD-50 mg/m2
D- 75 mg/m2
PLD (CAELYX)
Harris et al. [8] 2001 58 58 MBC 224 108 116 Doxorubicin LED- 75 mg
Doxorubicin- 75 mg/m2
Myocet
Batist et al. [16] 2001 55 54 MBC 297 142 155 Doxorubicin LED-60 mg/m2
Doxo-60 mg/m2
Myocet
O’Brien et al. [14] 2003 59 58 MBC 509 254 255 Doxorubicin PLD-50 mg/m2
D- 60 mg/m2
PLD
Dimopoulos et al. [25] 2003 66 65 MM 259 132 127 Doxorubicin doxil-40 mg
doxo-9 mg/m2
Doxil bolus
Chan et al. [26] 2004 54 54 MBC 160 80 80 Epirubicin LD-75 mg/m2
D-75 mg/m2
Myocet
Rifkin et al. [27] 2005 60 60 MM 192 97 95 Doxorubicin Doxil-40 mg
Doxo-9 mg/m2
Doxil
  1. Abbreviations:AIDS-KS: Acquired immune deficiency syndrome- Kaposi Sarcoma; D: Doxorubicin; LD: Liposomal Doxorubicin; L Dauno: Liposomal Daunorubicin; MBC: Metastatic Breast Cancer; MM: Multiple Myeloma; PLD: Pegylated Liposomal Doxorubicin.